Artivion Reports Third Quarter 2026 Financial Results
Artivion delivered Q3 2026 revenue of $123.8 million, up 9% year-over-year on both GAAP and constant currency bases, led by 13% constant currency On-X growth and 12% stent graft growth. Profitability deteriorated: GAAP results swung to a $(7.9) million net loss ($(0.16) per share) from $6.5 million net income a year ago, non-GAAP EPS halved to $0.08, adjusted EBITDA fell 8% to $22.5 million, and Q3 free cash flow was $(17.6) million. Management narrowed FY2026 guidance to revenue of $484-$492 million (8-10% constant currency growth) and adjusted EBITDA of $93-$98 million, citing the ~$8 million Endospan acquisition expense. Pipeline catalysts remain intact: U.S.
Key figures
- Revenue
- $123.8 million
- Guidance
- FY2026 revenue narrowed to $484-$492 million (8-10% adjusted constant currency growth) from $480-$496 million; adjusted EBITDA narrowed to $93-$98 million from $92-$99 million
- Revenue Yoy
- 9%
- Cash
- 48399000
- Non gaap eps
- 0.08
- Long term debt
- 363787000
- Adjusted ebitda
- 22500000
- Adjusted ebitda yoy
- -8%
- Us arch market opportunity
- $330 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.